Bausch Health Companies Inc. (NYSE: BHC) was founded in 1983, formerly known as Valeant Pharmaceuticals International (or: Weilang Pharmaceuticals, Valeant International Pharmaceuticals, Valeant Pharmaceuticals International, Inc.) (formerly NYSE: VRX ), headquartered in Laval, Canada, with 20,700 full-time employees, is a generic and non-prescription drugs and medical device production and sales company, the largest pharmaceutical company in Canada, and one of the largest contact lens manufacturers in the world.
Bausch Health Companies Inc. (BHC):
Boshikang focuses on the research and development and pharmacy of neurology, dermatology and infectious diseases. There are many drugs in late-stage clinical trials and several are currently on the market. In addition, Valeant has more than 500 products with a history dating back to the 1960s.
Valeant’s products mainly include:
- Solodyn, Ziana, Acanya, Atralin, Retin-treatment of acne and red pus papules
- Wellbutrin XL-treatment of severe depression in adults
- Jublia-treatment of athlete’s foot
- Xenazine-treatment of chorea
- Targretin-treatment of skin T cell lymphoma
- Arestin-a slow-release subgingival antibiotic
- PROVENGE-for the treatment of prostate cancer
- Prolensa-treatment of inflammation and pain after cataract surgery
- Duromine-weight loss pills
- Zovirax-for the treatment of antiviral recurrent herpes labialis and genital herpes
- Syprine-treatment of Wilson’s disease
- Elidel-treatment of atopic dermatitis
- Lotemax-for inflammation and pain after surgery
- PreserVision-Antioxidant for eyes, supplement of vitamins and minerals
- CeraVe-Rebuild and repair the skin barrier
- ReNu Multiplus-Contact Lens Cleaner
- Biotrue-contact lens cleaner
- Ocuvite-Lutein and Vitamin Mineral Supplement
- Boston-Contact Lens Cleaner
- Artelac-Treatment of dry eyes, eye drops
- AntiGrippin-for acute and chronic respiratory viral infections and influenza
- Bedoyecta-product of vitamin B complex
- SofLens-Daily Disposable Contact Lenses
- PureVision-contact lenses
- Various eye surgery products
- Biotrue-Daily Disposable (Disposable) Contact Lenses
- Aesthetic application of medical equipment system
- Bausch + Lomb Ultra (Bausch & Lomb)-Contact Lenses
In addition, Valeant Pharmaceuticals also manufactures and sells a variety of ophthalmic diseases (such as: glaucoma), high blood pressure and angina pectoris.
Bausch Health Companies Inc. (BHC) History:
- In 2008, the Swedish pharmaceutical company Meda AB acquired the Western and Eastern European branches of Valeant Pharmaceuticals for US$392 million.
- In September 2008, Valeant acquired Coria Laboratories, Ltd, a company called Coria Laboratories, Ltd. for USD 95 million.
- In November 2008, DermaTech was acquired for $12.6 million.
- In December 2008, Dow Pharmaceutical Sciences, Inc was acquired for US$285 million.
- In July 2009, Valia announced the acquisition of Tecnofarma, a Mexican pharmaceutical company.
- In December 2009, Valeant announced that its Canadian subsidiary had acquired Canadian cosmeceutical company Laboratoire Dr. Renaud for 23 million Canadian dollars.
- In March 2010, the company announced the acquisition of a Brazilian generic drug company for $28 million + $28 million.
- In April 2010, the company announced that its Canadian subsidiary had acquired Vital Science Corp. for CAD 1050.
- In May 2010, Fanlia Pharmaceuticals announced the acquisition of Aton Pharmaceuticals for US$318 million.
- On September 28, 2010, Biovail acquired Valeant Pharmaceuticals, and the new company was named Valeant.
- In March 2011, Valeant tried to acquire Cephalon Inc for $5.7 billion, but failed. But later, it acquired PharmaSwiss SA.
- In August 2011, it acquired 87.2% of the outstanding shares of Sanitas Group for 314 million euros.
- In December 2011, iNova was acquired for US$625 million. In the same month, it acquired Dermik, Sanofi ‘s dermatology department , for USD 75 million .
- In January 2012, Probiotica Laboratorios Ltda, a Brazilian sports nutrition company acquired by Valia Pharmaceuticals for US$150 million.
- In February 2012, it acquired Eyetech Inc., an ophthalmic biotechnology company.
- In April 2012, Pedinol was acquired.
- In June 2012, OraPharma was acquired for a total price of US$456 million.
- In August 2012, Valia Pharmaceuticals acquired the skincare company Medicis Pharmaceutical for US$2.6 billion.
- In January 2013, it acquired the Russian company Natur Produkt for US$163 million.
- In March 2013, Valeant acquired Obagi Medical Products, Inc. of Obagi Medical Products, Inc. for $19.75 per share.
- In May 2013, it acquired Bausch & Lomb , a well-known manufacturer of contact lenses, care solutions, and surgical equipment for US$8.57 billion . Valeant’s existing eye care business will be merged into Rochester, New York, where Bausch & Lomb is headquartered.
- In January 2014, it acquired Solta Medical, Inc., a pharmaceutical company, for USD 250 million.
- In April 2014, it sought to acquire Allergan , the leading American medical beauty leader, for US$53 billion , but it ended in failure. Allergan was eventually acquired by Actavis ACT in March 2015 .
- In February 2015, Valia Pharmaceuticals acquired Salix Pharmaceuticals for US$14.5 billion;
- In October 2015 (as of October 28), due to short selling by the well-known short-selling agency Citron, the stock price has fallen by more than 30% within 9 trading days;
- On October 29, 2015, CVS , the largest chain of pharmacies in the United States, announced that it would remove Philidor, a specialty pharmacy, from its pharmacy network list. The mysterious relationship between Valeant and Philidor officially shorted Citron as the attack point. Valeant plunged more than 13 after the trading day. %;
- On June 8, 2018, Valia Pharmaceuticals International announced that it will soon be renamed Bausch Health Companies.
- In July 2018, Valia Pharmaceuticals International officially changed its name to Bausch Health Companies, and adopted a new stock code: BHC.
Boshikang (Faliya Pharmaceutical International) acquisition history, click to view larger image